22nd Century Group Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de 22nd Century Group de 34.5% y 21.3% respectivamente, mientras que el BPA crecerá en un 61.3% al año.

Información clave

34.5%

Tasa de crecimiento de los beneficios

61.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Tobacco	19.4%
Tasa de crecimiento de los ingresos	21.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	28 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher

Apr 02

Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook

Aug 20

With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For

Jun 14

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Jan 13

22nd Century adds Creager as distribution partner for its VLN cigarettes in Colorado

Oct 03

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:XXII - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	35	-33	N/A	N/A	1
12/31/2024	34	-42	N/A	N/A	1
12/31/2023	22	-65	-61	-55	N/A
9/30/2023	84	-139	-75	-69	N/A
6/30/2023	84	-78	-75	-69	N/A
3/31/2023	75	-69	-67	-61	N/A
12/31/2022	28	-37	-56	-52	N/A
9/30/2022	49	-47	-41	-37	N/A
6/30/2022	39	-44	-32	-30	N/A
3/31/2022	30	-36	-28	-27	N/A
12/31/2021	31	-33	-24	-23	N/A
9/30/2021	23	-25	-22	-21	N/A
6/30/2021	25	-20	-17	-16	N/A
3/31/2021	28	-21	-15	-15	N/A
12/31/2020	28	-20	-16	-16	N/A
9/30/2020	28	-20	-16	-16	N/A
6/30/2020	27	-26	-18	-17	N/A
3/31/2020	27	-29	-16	-15	N/A
12/31/2019	26	-27	-16	-15	N/A
9/30/2019	26	-29	-18	-17	N/A
6/30/2019	26	-13	-20	-18	N/A
3/31/2019	27	-11	-20	-19	N/A
12/31/2018	26	-8	-19	-18	N/A
9/30/2018	25	-3	-16	-15	N/A
6/30/2018	24	-12	-15	-13	N/A
3/31/2018	20	-9	-14	-13	N/A
12/31/2017	17	-13	-14	-12	N/A
9/30/2017	14	-12	N/A	-12	N/A
6/30/2017	13	-11	N/A	-11	N/A
3/31/2017	11	-11	N/A	-10	N/A
12/31/2016	12	-12	N/A	-10	N/A
9/30/2016	12	-12	N/A	-10	N/A
6/30/2016	11	-12	N/A	-10	N/A
3/31/2016	11	-10	N/A	-8	N/A
12/31/2015	9	-11	N/A	-7	N/A
9/30/2015	6	-14	N/A	-8	N/A
6/30/2015	3	-14	N/A	-8	N/A
3/31/2015	1	-14	N/A	-8	N/A
12/31/2014	1	-16	N/A	-7	N/A
9/30/2014	8	-18	N/A	2	N/A
6/30/2014	8	-30	N/A	3	N/A
3/31/2014	8	-29	N/A	4	N/A
12/31/2013	7	-26	N/A	4	N/A
9/30/2013	0	-23	N/A	-3	N/A
6/30/2013	0	-8	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que XXII siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que XXII siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que XXII siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (21.3% al año) de XXII crezcan más rápidamente que los del mercado US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (21.3% al año) de XXII crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de XXII se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

22nd Century Group Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

Consensus EPS estimates fall by 67%

Consensus revenue estimates fall by 11%

Price target decreased by 27% to US$31.19

Consensus revenue estimates increase by 10%, EPS downgraded

22nd Century Group, Inc. Provides Revenue Guidance for the Full Year 2023

Recent updates

22nd Century Group, Inc. announced that it has received $4.2 million in funding

22nd Century Group, Inc. has filed a Follow-on Equity Offering in the amount of $4.237199 million.

22nd Century Group Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Nasdaq's Listing Rule 5550(b)(1)

Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher

New major risk - Share price stability

No longer forecast to breakeven

Full year 2023 earnings released: US$3.12 loss per share (vs US$4.65 loss in FY 2022)

22nd Century Group, Inc. to Report Q4, 2023 Results on Mar 28, 2024

22Nd Century Group, Inc. Announces Termination of Peter Ferola as the Chief Legal Officer and Corporate Secretary

High number of new directors

22Nd Century Group, Inc. Appoints Lawrence (Larry) Firestone as Chief Executive Officer

Specialty Acquisition Corporation entered into a equity purchase agreement to acquire Substantially all of GVB hemp/cannabis business from 22nd Century Group, Inc. (NasdaqCM:XXII) and ESI Holdings, LLC for $2.3 million.

Consensus EPS estimates fall by 67%

New major risk - Market cap size

22nd Century Group Receives Non-Compliance Letter from Nasdaq

22nd Century Group, Inc. Continues VLN Expansion, Now Retailing in More Than 5,100 Stores

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

22Nd Century Group, Inc. Adds 1,200 Drug Store Locations Selling VLN in Five States

Consensus revenue estimates fall by 11%

Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook

Price target decreased by 27% to US$31.19

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Pomerantz LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of 22nd Century Group, Inc. Common Stock

High number of new directors

22Nd Century Group, Inc. Announces Chief Executive Officer Changes

22nd Century Group Regains Compliance with Nasdaq Listing Standards

22Nd Century Group, Inc. Announces Its Vln(R) Reduced Nicotine Content C-Stores

New minor risk - Share price stability

22nd Century Announces 1-For-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

22nd Century Group, Inc. Announces Production of VLN(R) Homogenized Tobacco Leaf Sheet

22nd Century Group, Inc. Announces VLN(R) Products Launch in Nevada to Help Smokers Smoke Less

With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For

22Nd Century Group, Inc. Launches Vln At #1 U.S. C-Store Chain in Texas, California and Florida

Consensus revenue estimates increase by 10%, EPS downgraded

22nd Century Group, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 11% to US$4.00

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

22nd Century Group, Inc. to Report Q1, 2023 Results on May 09, 2023

Consensus EPS estimates fall by 16%

Full year 2022 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. (NasdaqCM:XXII) acquired Rx Pharmatech Ltd for $0.65 million.

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Forecast to breakeven in 2025

Key Executive notifies of intention to sell stock

22Nd Century Group, Inc. Appoints John J. Miller as an Executive Officer and President of Tobacco

High number of new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

22nd Century Group, Inc. to Report Q3, 2022 Results on Nov 08, 2022

22nd Century adds Creager as distribution partner for its VLN cigarettes in Colorado

High number of new directors

22Nd Century Group Appoints Lucille S. Salhany to Its Board

22Nd Century Group, Inc. Announces Executive Changes

22nd Century Group to expand sales of VLN tobacco cigarettes

22nd Century Group (NASDAQ:XXII) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

22nd Century GAAP EPS of -$0.06 in-line, revenue of $14.5M beats by $3.21M

Consensus forecasts updated

22nd Century Group, Inc. announced that it has received $35.000009 million in funding

22nd Century Group, Inc. to Report Q2, 2022 Results on Aug 09, 2022

22nd Century Group launches $35M securities offering

22Nd Century Group, Inc. Announces the Appointment of R. Hugh Kinsman as Its Chief Financial Officer

22nd Century Group, Inc. announced that it has received funding

22nd Century Group Announces John J. Miller Joins Its Tobacco Business

Key Executive exercised options to buy US$179k worth of stock.

22nd Century Group, Inc. (NasdaqCM:XXII) acquired GVB BioPharma for $51.7 million.